{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:03:21Z","timestamp":1788779001425,"version":"build-2803163510"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["45\/17\/2019-BMS\/PHA"],"award-info":[{"award-number":["45\/17\/2019-BMS\/PHA"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Aromatase enzyme plays a fundamental role in the development of estrogen receptors, and due to this functionality, the enzyme has gained significant attention as a therapeutic for reproductive disorders and cancer diseases. The currently employed aromatase inhibitors have severe side effects whereas our novel aromatase inhibitor is more selective and less toxic, therefore has greater potential to be developed as a drug. The research framework of this study is to identify a potent inhibitor for the aromatase target by profiling molecular descriptors of the ligand and to find a functional pocket in the target by docking and MD simulations. For assessing cellular and metabolic activities as indicators of cell viability and cytotoxicity,\u00a0in-vitro\u00a0studies were performed by using the colorimetric MTT assay. Aromatase activities were determined by a fluorometric method. Cell morphology was assessed by phase-contrast light microscopy. Flow cytometry and Annexin V-FITC\/PI staining assay determined cell cycle distribution and apoptosis. This study reports that CHEMBL708 (Ziprasidone) is the most promising compound that showed excellent aromatase inhibitory activity. By using better drug design methods and experimental studies, our study identified a novel compound that could be effective as a high-potential drug candidate against aromatase enzyme. We conclude that the compound ziprasidone effectively blocks the cell cycle at the G1-S phase and induces cancer cell death. Further, in-vivo studies are vital for developing ziprasidone as an anticancer agent. Lastly, our research outcomes based on the results of the in-silico experiments may pave the way for identifying effective drug candidates for therapeutic use in breast cancer.<\/jats:p>","DOI":"10.1038\/s41598-023-43789-1","type":"journal-article","created":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T11:01:38Z","timestamp":1696244498000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["In-silico and in-vitro study reveals ziprasidone as a potential aromatase inhibitor against breast carcinoma"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6679-3486","authenticated-orcid":false,"given":"Ankita","family":"Sahu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9832-2830","authenticated-orcid":false,"given":"Shaban","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2854-5857","authenticated-orcid":false,"given":"Khalid","family":"Imtiyaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4460-8969","authenticated-orcid":false,"given":"Ajeeshkumar","family":"Kizhakkeppurath Kumaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7219-9686","authenticated-orcid":false,"given":"Mojahidul","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3646-6828","authenticated-orcid":false,"given":"Khalid","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7628-0772","authenticated-orcid":false,"given":"Murugesh","family":"Easwaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3688-3901","authenticated-orcid":false,"given":"Asha","family":"Kurukkan Kunnath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4449-7819","authenticated-orcid":false,"given":"Moshahid A.","family":"Rizvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1489-1871","authenticated-orcid":false,"given":"Saurabh","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,2]]},"reference":[{"key":"43789_CR1","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMra023246","volume":"348","author":"IE Smith","year":"2003","unstructured":"Smith, I. E. & Dowsett, M. Aromatase inhibitors in breast cancer. N. Engl. J. Med. 348, 2431\u20132442 (2003).","journal-title":"N. Engl. J. Med."},{"key":"43789_CR2","doi-asserted-by":"publisher","first-page":"2200046","DOI":"10.1002\/prca.202200046","volume":"17","author":"A Kizhakkeppurath Kumaran","year":"2023","unstructured":"Kizhakkeppurath Kumaran, A. et al. Proteoglycans in breast cancer, identification and characterization by LC-MS\/MS assisted proteomics approach: A review. Proteom. Clin. Appl. 17, 2200046 (2023).","journal-title":"Proteom. Clin. Appl."},{"key":"43789_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/bcr423","volume":"4","author":"KB Michels","year":"2002","unstructured":"Michels, K. B. The contribution of the environment (especially diet) to breast cancer risk. Breast Cancer Res. 4, 58 (2002).","journal-title":"Breast Cancer Res."},{"key":"43789_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/bcr628","volume":"5","author":"RC Travis","year":"2003","unstructured":"Travis, R. C. & Key, T. J. Oestrogen exposure and breast cancer risk. Breast Cancer Res. BCR 5, 239 (2003).","journal-title":"Breast Cancer Res. BCR"},{"key":"43789_CR5","doi-asserted-by":"publisher","first-page":"e1596","DOI":"10.1002\/wsbm.1596","volume":"15","author":"A Sahu","year":"2023","unstructured":"Sahu, A., Raza, K., Pradhan, D., Jain, A. K. & Verma, S. Cyclooxygenase-2 as a therapeutic target against human breast cancer: A comprehensive review. WIREs Mech. Dis. 15, e1596 (2023).","journal-title":"WIREs Mech. Dis."},{"key":"43789_CR6","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3389\/fphar.2015.00283","volume":"6","author":"A Appert-Collin","year":"2015","unstructured":"Appert-Collin, A., Hubert, P., Cr\u00e9mel, G. & Bennasroune, A. Role of ErbB receptors in cancer cell migration and invasion. Front. Pharmacol. 6, 283 (2015).","journal-title":"Front. Pharmacol."},{"key":"43789_CR7","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1124\/jpet.105.084145","volume":"315","author":"A Arora","year":"2005","unstructured":"Arora, A. & Scholar, E. M. Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther. 315, 971\u2013979 (2005).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"43789_CR8","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/annonc\/mdg365","volume":"14","author":"G Atalay","year":"2003","unstructured":"Atalay, G., Cardoso, F., Awada, A. & Piccart, M. J. Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Ann. Oncol. 14, 1346\u20131363 (2003).","journal-title":"Ann. Oncol."},{"key":"43789_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-981-19-8249-1_2","volume-title":"Protein-Based Therapeutics","author":"MK Yadav","year":"2023","unstructured":"Yadav, M. K. et al. Clinical applications of protein-based therapeutics. In Protein-Based Therapeutics (eds Singh, D. B. & Tripathi, T.) 23\u201347 (Springer Nature, 2023). https:\/\/doi.org\/10.1007\/978-981-19-8249-1_2."},{"key":"43789_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s40199-023-00467-x","author":"A Sahu","year":"2023","unstructured":"Sahu, A. et al. In silico screening, synthesis, characterization and biological evaluation of novel anticancer agents as potential COX-2 inhibitors. DARU J. Pharm. Sci. https:\/\/doi.org\/10.1007\/s40199-023-00467-x (2023).","journal-title":"DARU J. Pharm. Sci."},{"key":"43789_CR11","doi-asserted-by":"publisher","first-page":"324","DOI":"10.6026\/97320630012324","volume":"12","author":"R Kumavath","year":"2016","unstructured":"Kumavath, R. et al. Novel aromatase inhibitors selection using induced fit docking and extra precision methods: Potential clinical use in ER-alpha-positive breast cancer. Bioinformation 12, 324\u2013331 (2016).","journal-title":"Bioinformation"},{"key":"43789_CR12","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/978-3-540-38918-7_236","volume-title":"Encyclopedia of Molecular Pharmacology","author":"D Shaheenah","year":"2008","unstructured":"Shaheenah, D., Fellow, S. G. K. & Buzdar, A. U. Aromatase. In Encyclopedia of Molecular Pharmacology (eds Offermanns, S. & Rosenthal, W.) 218\u2013221 (Springer, 2008). https:\/\/doi.org\/10.1007\/978-3-540-38918-7_236."},{"key":"43789_CR13","doi-asserted-by":"publisher","first-page":"e594656","DOI":"10.1155\/2015\/594656","volume":"2015","author":"ED Lephart","year":"2015","unstructured":"Lephart, E. D. Modulation of aromatase by phytoestrogens. Enzyme Res. 2015, e594656 (2015).","journal-title":"Enzyme Res."},{"key":"43789_CR14","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10519-012-9532-3","volume":"42","author":"H Anthoni","year":"2012","unstructured":"Anthoni, H. et al. The aromatase gene CYP19A1: Several genetic and functional lines of evidence supporting a role in reading, speech and language. Behav. Genet. 42, 509\u2013527 (2012).","journal-title":"Behav. Genet."},{"key":"43789_CR15","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1111\/jog.13743","volume":"44","author":"T Mori","year":"2018","unstructured":"Mori, T. et al. Aromatase as a target for treating endometriosis. J. Obstet. Gynaecol. Res. 44, 1673\u20131681 (2018).","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"43789_CR16","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1634\/theoncologist.11-6-553","volume":"11","author":"K Altundag","year":"2006","unstructured":"Altundag, K. & Ibrahim, N. K. Aromatase inhibitors in breast cancer: An overview. Oncologist 11, 553\u2013562 (2006).","journal-title":"Oncologist"},{"key":"43789_CR17","first-page":"126","volume":"61","author":"I Czajka-Oraniec","year":"2010","unstructured":"Czajka-Oraniec, I. & Simpson, E. R. Aromatase research and its clinical significance. Endokrynol. Pol. 61, 126\u2013134 (2010).","journal-title":"Endokrynol. Pol."},{"key":"43789_CR18","doi-asserted-by":"publisher","first-page":"S116","DOI":"10.1067\/mjd.2001.117432","volume":"45","author":"LR Nelson","year":"2001","unstructured":"Nelson, L. R. & Bulun, S. E. Estrogen production and action. J. Am. Acad. Dermatol. 45, S116-124 (2001).","journal-title":"J. Am. Acad. Dermatol."},{"key":"43789_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jsbmb.2015.07.018","volume":"161","author":"HJ Chan","year":"2016","unstructured":"Chan, H. J., Petrossian, K. & Chen, S. Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and \u2013 resistant breast cancer cells. J. Steroid Biochem. Mol. Biol. 161, 73\u201383 (2016).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"43789_CR20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1210\/er.2008-0016","volume":"30","author":"RJ Santen","year":"2009","unstructured":"Santen, R. J., Brodie, H., Simpson, E. R., Siiteri, P. K. & Brodie, A. History of aromatase: Saga of an important biological mediator and therapeutic target. Endocr. Rev. 30, 343\u2013375 (2009).","journal-title":"Endocr. Rev."},{"key":"43789_CR21","doi-asserted-by":"publisher","first-page":"6981","DOI":"10.3390\/app10196981","volume":"10","author":"C Cava","year":"2020","unstructured":"Cava, C. & Castiglioni, I. Integration of molecular docking and in vitro studies: A powerful approach for drug discovery in breast cancer. Appl. Sci. 10, 6981 (2020).","journal-title":"Appl. Sci."},{"key":"43789_CR22","doi-asserted-by":"publisher","first-page":"W612","DOI":"10.1093\/nar\/gkv352","volume":"43","author":"M Davies","year":"2015","unstructured":"Davies, M. et al. ChEMBL web services: Streamlining access to drug discovery data and utilities. Nucleic Acids Res. 43, W612\u2013W620 (2015).","journal-title":"Nucleic Acids Res."},{"key":"43789_CR23","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd3078","volume":"9","author":"SM Paul","year":"2010","unstructured":"Paul, S. M. et al. How to improve R&D productivity: The pharmaceutical industry\u2019s grand challenge. Nat. Rev. Drug Discov. 9, 203\u2013214 (2010).","journal-title":"Nat. Rev. Drug Discov."},{"key":"43789_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.addr.2016.04.029","volume":"101","author":"CA Lipinski","year":"2016","unstructured":"Lipinski, C. A. Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions. Adv. Drug Deliv. Rev. 101, 34\u201341 (2016).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"43789_CR25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1056-8719(00)00107-6","volume":"44","author":"CA Lipinski","year":"2000","unstructured":"Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44, 235\u2013249 (2000).","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"43789_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-94-007-6169-8_59-1","volume-title":"Handbook of Computational Chemistry","author":"HK Shin","year":"2016","unstructured":"Shin, H. K., Kang, Y.-M. & No, K. T. Predicting ADME properties of chemicals. In Handbook of Computational Chemistry (ed. Leszczynski, J.) 1\u201337 (Springer Netherlands, 2016). https:\/\/doi.org\/10.1007\/978-94-007-6169-8_59-1."},{"key":"43789_CR27","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.2174\/15680266113139990033","volume":"13","author":"F Cheng","year":"2013","unstructured":"Cheng, F., Li, W., Liu, G. & Tang, Y. In silico ADMET prediction: Recent advances, current challenges and future trends. Curr. Top. Med. Chem. 13, 1273\u20131289 (2013).","journal-title":"Curr. Top. Med. Chem."},{"key":"43789_CR28","doi-asserted-by":"publisher","first-page":"e0156156","DOI":"10.1371\/journal.pone.0156156","volume":"11","author":"S Shahbazi","year":"2016","unstructured":"Shahbazi, S. et al. Drug targets for cardiovascular-safe anti-inflammatory: In silico rational drug studies. PLoS One 11, e0156156 (2016).","journal-title":"PLoS One"},{"key":"43789_CR29","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1016\/j.bmc.2017.05.054","volume":"25","author":"SS Thakkar","year":"2017","unstructured":"Thakkar, S. S., Thakor, P., Doshi, H. & Ray, A. 1,2,4-Triazole and 1,3,4-oxadiazole analogues: Synthesis, MO studies, in silico molecular docking studies, antimalarial as DHFR inhibitor and antimicrobial activities. Bioorg. Med. Chem. 25, 4064\u20134075 (2017).","journal-title":"Bioorg. Med. Chem."},{"key":"43789_CR30","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/978-1-4939-2074-7_26","volume":"1250","author":"L Tolosa","year":"2015","unstructured":"Tolosa, L., Donato, M. T. & G\u00f3mez-Lech\u00f3n, M. J. General cytotoxicity assessment by means of the MTT assay. Methods Mol. Biol. 1250, 333\u2013348 (2015).","journal-title":"Methods Mol. Biol."},{"key":"43789_CR31","doi-asserted-by":"publisher","DOI":"10.3791\/2597","author":"AM Rieger","year":"2011","unstructured":"Rieger, A. M., Nelson, K. L., Konowalchuk, J. D. & Barreda, D. R. Modified annexin V\/propidium iodide apoptosis assay for accurate assessment of cell death. J. Vis. Exp. https:\/\/doi.org\/10.3791\/2597 (2011).","journal-title":"J. Vis. Exp."},{"key":"43789_CR32","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1021\/ci800324m","volume":"49","author":"TA Halgren","year":"2009","unstructured":"Halgren, T. A. Identifying and characterizing binding sites and assessing druggability. J. Chem. Inf. Model. 49, 377\u2013389 (2009).","journal-title":"J. Chem. Inf. Model."},{"key":"43789_CR33","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.2174\/1568026616666161117112604","volume":"17","author":"X Zhang","year":"2017","unstructured":"Zhang, X., Perez-Sanchez, H. & Lightstone, F. C. A comprehensive docking and MM\/GBSA rescoring study of ligand recognition upon binding antithrombin. Curr. Top. Med. Chem. 17, 1631\u20131639 (2017).","journal-title":"Curr. Top. Med. Chem."},{"key":"43789_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1744-859X-12-1","volume":"12","author":"DM Gardner","year":"2013","unstructured":"Gardner, D. M. et al. Evidence review and clinical guidance for the use of ziprasidone in Canada. Ann. Gen. Psychiatry 12, 1 (2013).","journal-title":"Ann. Gen. Psychiatry"},{"key":"43789_CR35","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00109-022-02181-8","volume":"100","author":"Y Yang","year":"2022","unstructured":"Yang, Y. et al. Ziprasidone suppresses pancreatic adenocarcinoma cell proliferation by targeting GOT1 to trigger glutamine metabolism reprogramming. J. Mol. Med. (Berl.) 100, 599\u2013612 (2022).","journal-title":"J. Mol. Med. (Berl.)"},{"key":"43789_CR36","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/nrd1523","volume":"3","author":"JG Lombardino","year":"2004","unstructured":"Lombardino, J. G. & Lowe, J. A. The role of the medicinal chemist in drug discovery\u2014Then and now. Nat. Rev. Drug Discov. 3, 853\u2013862 (2004).","journal-title":"Nat. Rev. Drug Discov."},{"key":"43789_CR37","doi-asserted-by":"publisher","first-page":"16152","DOI":"10.1021\/acsomega.2c01497","volume":"7","author":"UA \u00c7evik","year":"2022","unstructured":"\u00c7evik, U. A. et al. Design, synthesis, and molecular modeling studies of a novel benzimidazole as an aromatase inhibitor. ACS Omega 7, 16152\u201316163 (2022).","journal-title":"ACS Omega"},{"key":"43789_CR38","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1038\/s41598-018-37796-w","volume":"9","author":"NA Razak","year":"2019","unstructured":"Razak, N. A. et al. Cytotoxicity of eupatorin in MCF-7 and MDA-MB-231 human breast cancer cells via cell cycle arrest, anti-angiogenesis and induction of apoptosis. Sci. Rep. 9, 1514 (2019).","journal-title":"Sci. Rep."},{"key":"43789_CR39","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/nar\/28.1.235","volume":"28","author":"HM Berman","year":"2000","unstructured":"Berman, H. M. et al. The protein data bank. Nucleic Acids Res. 28, 235\u2013242 (2000).","journal-title":"Nucleic Acids Res."},{"key":"43789_CR40","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","volume":"27","author":"GM Sastry","year":"2013","unstructured":"Sastry, G. M., Adzhigirey, M., Day, T., Annabhimoju, R. & Sherman, W. Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments. J. Comput. Aided Mol. Des. 27, 221\u2013234 (2013).","journal-title":"J. Comput. Aided Mol. Des."},{"key":"43789_CR41","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1107\/S0021889892009944","volume":"26","author":"RA Laskowski","year":"1993","unstructured":"Laskowski, R. A., MacArthur, M. W., Moss, D. S. & Thornton, J. M. PROCHECK: A program to check the stereochemical quality of protein structures. J. Appl. Cryst. 26, 283\u2013291 (1993).","journal-title":"J. Appl. Cryst."},{"key":"43789_CR42","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1080\/10799893.2017.1342129","volume":"37","author":"A Sahu","year":"2017","unstructured":"Sahu, A., Patra, P. K., Yadav, M. K. & Varma, M. Identification and characterization of ErbB4 kinase inhibitors for effective breast cancer therapy. J. Recept. Signal Transduct. Res. 37, 470\u2013480 (2017).","journal-title":"J. Recept. Signal Transduct. Res."},{"key":"43789_CR43","doi-asserted-by":"publisher","first-page":"D1100","DOI":"10.1093\/nar\/gkr777","volume":"40","author":"A Gaulton","year":"2012","unstructured":"Gaulton, A. et al. ChEMBL: A large-scale bioactivity database for drug discovery. Nucleic Acids Res. 40, D1100\u2013D1107 (2012).","journal-title":"Nucleic Acids Res."},{"key":"43789_CR44","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jsbmb.2009.09.012","volume":"118","author":"D Ghosh","year":"2010","unstructured":"Ghosh, D., Griswold, J., Erman, M. & Pangborn, W. X-ray structure of human aromatase reveals an androgen-specific active site. J. Steroid Biochem. Mol. Biol. 118, 197\u2013202 (2010).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"43789_CR45","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1021\/jm0306430","volume":"47","author":"RA Friesner","year":"2004","unstructured":"Friesner, R. A. et al. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 47, 1739\u20131749 (2004).","journal-title":"J. Med. Chem."},{"key":"43789_CR46","doi-asserted-by":"publisher","first-page":"13384","DOI":"10.3390\/molecules200713384","volume":"20","author":"LG Ferreira","year":"2015","unstructured":"Ferreira, L. G., Dos Santos, R. N., Oliva, G. & Andricopulo, A. D. Molecular docking and structure-based drug design strategies. Molecules 20, 13384\u201313421 (2015).","journal-title":"Molecules"},{"key":"43789_CR47","doi-asserted-by":"publisher","first-page":"6177","DOI":"10.1021\/jm051256o","volume":"49","author":"RA Friesner","year":"2006","unstructured":"Friesner, R. A. et al. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem. 49, 6177\u20136196 (2006).","journal-title":"J. Med. Chem."},{"key":"43789_CR48","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","volume":"10","author":"S Genheden","year":"2015","unstructured":"Genheden, S. & Ryde, U. The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities. Expert Opin. Drug Discov. 10, 449\u2013461 (2015).","journal-title":"Expert Opin. Drug Discov."},{"key":"43789_CR49","doi-asserted-by":"publisher","first-page":"9478","DOI":"10.1021\/acs.chemrev.9b00055","volume":"119","author":"E Wang","year":"2019","unstructured":"Wang, E. et al. End-point binding free energy calculation with MM\/PBSA and MM\/GBSA: Strategies and applications in drug design. Chem. Rev. 119, 9478\u20139508 (2019).","journal-title":"Chem. Rev."},{"key":"43789_CR50","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/med.20067","volume":"26","author":"H Alonso","year":"2006","unstructured":"Alonso, H., Bliznyuk, A. A. & Gready, J. E. Combining docking and molecular dynamic simulations in drug design. Med. Res. Rev. 26, 531\u2013568 (2006).","journal-title":"Med. Res. Rev."},{"key":"43789_CR51","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.3390\/ijms20184574","volume":"20","author":"PHM Torres","year":"2019","unstructured":"Torres, P. H. M., Sodero, A. C. R., Jofily, P. & Silva-Jr, F. P. Key topics in molecular docking for drug design. Int. J. Mol. Sci. 20, 4574 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"43789_CR52","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2174\/1570180819666220128122553","volume":"20","author":"A Sahu","year":"2023","unstructured":"Sahu, A. et al. Computational screening for finding new potent COX-2 inhibitors as anticancer agents. Lett. Drug Des. Discov. 20, 213\u2013224 (2023).","journal-title":"Lett. Drug Des. Discov."},{"key":"43789_CR53","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1021\/ci400040d","volume":"53","author":"KM Elokely","year":"2013","unstructured":"Elokely, K. M. & Doerksen, R. J. Docking challenge: Protein sampling and molecular docking performance. J. Chem. Inf. Model. 53, 1934\u20131945 (2013).","journal-title":"J. Chem. Inf. Model."},{"key":"43789_CR54","doi-asserted-by":"publisher","first-page":"21","DOI":"10.29007\/z2wx","volume":"70","author":"A Sahu","year":"2020","unstructured":"Sahu, A. et al. In silico library design, screening and MD simulation of COX-2 inhibitors for anticancer activity. BICOB (EPiC Ser. Comput.) 70, 21\u201332 (2020).","journal-title":"BICOB (EPiC Ser. Comput.)"},{"key":"43789_CR55","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/cmdc.200600155","volume":"1","author":"U Norinder","year":"2006","unstructured":"Norinder, U. & Bergstr\u00f6m, C. A. S. Prediction of ADMET properties. ChemMedChem 1, 920\u2013937 (2006).","journal-title":"ChemMedChem"},{"key":"43789_CR56","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1080\/07391102.2016.1244492","volume":"35","author":"T Dasari","year":"2017","unstructured":"Dasari, T. et al. Design of novel lead molecules against RhoG protein as cancer target\u2014A computational study. J. Biomol. Struct. Dyn. 35, 3119\u20133139 (2017).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"43789_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/2193-1801-2-353","author":"F Ntie-Kang","year":"2013","unstructured":"Ntie-Kang, F. An in silico evaluation of the ADMET profile of the StreptomeDB database. Springerplus https:\/\/doi.org\/10.1186\/2193-1801-2-353 (2013).","journal-title":"Springerplus"},{"key":"43789_CR58","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0169-409X(02)00004-2","volume":"54","author":"WJ Egan","year":"2002","unstructured":"Egan, W. J. & Lauri, G. Prediction of intestinal permeability. Adv. Drug Deliv. Rev. 54, 273\u2013289 (2002).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"43789_CR59","doi-asserted-by":"publisher","first-page":"104665","DOI":"10.1016\/j.bioorg.2021.104665","volume":"108","author":"M Rana","year":"2021","unstructured":"Rana, M. et al. Pyrazoline analogs as potential anticancer agents and their apoptosis, molecular docking, MD simulation, DNA binding and antioxidant studies. Bioorg. Chem. 108, 104665 (2021).","journal-title":"Bioorg. Chem."},{"key":"43789_CR60","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/nsb0902-646","volume":"9","author":"M Karplus","year":"2002","unstructured":"Karplus, M. & McCammon, J. A. Molecular dynamics simulations of biomolecules. Nat. Struct. Biol. 9, 646\u2013652 (2002).","journal-title":"Nat. Struct. Biol."},{"key":"43789_CR61","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1021\/cr040426m","volume":"106","author":"SA Adcock","year":"2006","unstructured":"Adcock, S. A. & McCammon, J. A. Molecular dynamics: Survey of methods for simulating the activity of proteins. Chem. Rev. 106, 1589\u20131615 (2006).","journal-title":"Chem. Rev."},{"key":"43789_CR62","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2023.2209673","author":"S Ahmad","year":"2023","unstructured":"Ahmad, S., Singh, V., Gautam, H. K. & Raza, K. Multisampling-based docking reveals Imidazolidinyl urea as a multitargeted inhibitor for lung cancer: An optimization followed multi-simulation and in-vitro study. J. Biomol. Struct. Dyn. https:\/\/doi.org\/10.1080\/07391102.2023.2209673 (2023).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"43789_CR63","doi-asserted-by":"publisher","DOI":"10.1007\/s11030-023-10648-0","author":"S Ahmad","year":"2023","unstructured":"Ahmad, S. & Raza, K. Identification of 5-nitroindazole as a multitargeted inhibitor for CDK and transferase kinase in lung cancer: A multisampling algorithm-based structural study. Mol. Divers. https:\/\/doi.org\/10.1007\/s11030-023-10648-0 (2023).","journal-title":"Mol. Divers."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43789-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43789-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43789-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T20:07:10Z","timestamp":1700338030000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43789-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,2]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["43789"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-43789-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2872883\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,2]]},"assertion":[{"value":"28 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16545"}}